Artiva biotherapeutics announces longer-term phase 1/2 data demonstrating prolonged durability for allonk® in combination with rituximab in patients with b-cell-non-hodgkin lymphoma at the asgct 28th annual meeting

64% (9/14) complete response rate with allonk + rituximab in heavily pretreated patients that were naÏve to prior car-t cell therapy, in line with approved auto-car-t therapies in aggressive b-nhl

CAR Ratings Summary

CAR Quant Ranking